The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space
Tài liệu tham khảo
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239
Zhu, 2018, Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors, Cancer Manag Res, 10, 2475, 10.2147/CMAR.S167400
Yarchoan, 2019, PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers, JCI Insight, 4, e126908, 10.1172/jci.insight.126908
Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498
Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2
Rizvi, 2018, Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384
Zhu, 2019, Association between tumor mutation burden (TMB) and outcomes of cancer patients treated with PD-1/PD-L1 inhibitions: a meta-analysis, Front Pharmacol, 10, 673, 10.3389/fphar.2019.00673
Laumont, 2018, Noncoding regions are the main source of targetable tumor-specific antigens, Sci Transl Med, 10, eaau5516, 10.1126/scitranslmed.aau5516
Yi, 2018, The role of neoantigen in immune checkpoint blockade therapy, Exp Hematol Oncol, 7, 28, 10.1186/s40164-018-0120-y
Pleasance, 2020, Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes, Nat Cancer, 1, 452, 10.1038/s43018-020-0050-6
Pender, 2021, Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumors, Clin Cancer Res, 27, 202, 10.1158/1078-0432.CCR-20-1163
Cheng, 2015, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J Mol Diagn, 17, 251, 10.1016/j.jmoldx.2014.12.006
Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696
McLaren, 2016, The Ensembl variant effect predictor, Genome Biol, 17, 122, 10.1186/s13059-016-0974-4
Hundal, 2020, PVACtools: a computational toolkit to identify and visualize cancer neoantigens, Cancer Immunol Res, 8, 409, 10.1158/2326-6066.CIR-19-0401
Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323
Jurtz, 2017, NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data, J Immunol, 199, 3360, 10.4049/jimmunol.1700893
O'Donnell, 2018, MHCflurry: open-source class I MHC binding affinity prediction, Cell Syst, 7, 129, 10.1016/j.cels.2018.05.014
Bhattacharya, 2017, Evaluation of machine learning methods to predict peptide binding to MHC class I proteins, bioRxiv
Boegel, 2012, HLA typing from RNA-Seq sequence reads, Genome Med, 4, 102, 10.1186/gm403
Pimentel, 2015, Keep me around: intron retention detection and analysis, arXiv
Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol, 10, R25, 10.1186/gb-2009-10-3-r25
Roberts, 2013, Streaming fragment assignment for real-time analysis of sequencing experiments, Nat Methods, 10, 71, 10.1038/nmeth.2251
Patro, 2017, Salmon provides fast and bias-aware quantification of transcript expression, Nat Methods, 14, 417, 10.1038/nmeth.4197
Butterfield, 2014, JAGuaR: junction alignments to genome for RNA-Seq reads, PLoS One, 9, e102398, 10.1371/journal.pone.0102398
Smart, 2018, Intron retention is a source of neoepitopes in cancer, Nat Biotechnol, 36, 1056, 10.1038/nbt.4239
Trapnell, 2010, Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation, Nat Biotechnol, 28, 511, 10.1038/nbt.1621
Wang, 2013, CPAT: coding-potential assessment tool using an alignment-free logistic regression model, Nucleic Acids Res, 41, e74, 10.1093/nar/gkt006
Xu, 2019, Assessment of tumor mutation burden calculation from gene panel sequencing data, Onco Targets Ther, 12, 3401, 10.2147/OTT.S196638
Heydt, 2020, Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing, Sci Rep, 10, 11387, 10.1038/s41598-020-68394-4
Fancello, 2019, Tumor mutational burden quantification from targeted gene panels: major advancements and challenges, J Immunother Cancer, 7, 183, 10.1186/s40425-019-0647-4
Scacheri, 2015, Mutations in the noncoding genome, Curr Opin Pediatr, 27, 659, 10.1097/MOP.0000000000000283
Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8
Luksza, 2017, A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature, 551, 517, 10.1038/nature24473
Kim, 2019, Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis, Cancers (Basel), 11, 1798, 10.3390/cancers11111798
Wu, 2019, The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis, Front Oncol, 9, 1161, 10.3389/fonc.2019.01161
Calis, 2015, Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs, Immunogenetics, 67, 85, 10.1007/s00251-014-0815-0
Finotello, 2019, Next-generation computational tools for interrogating cancer immunity, Nat Rev Genet, 20, 724, 10.1038/s41576-019-0166-7
Richters, 2019, Best practices for bioinformatic characterization of neoantigens for clinical utility, Genome Med, 11, 56, 10.1186/s13073-019-0666-2
Brennick, 2020, An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection, J Clin Invest, 131, e142823, 10.1172/JCI142823
Wood, 2020, Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival, Genome Med, 12, 33, 10.1186/s13073-020-00729-2
Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946
Johnson, 2016, Targeted next generation sequencing identifies markers of response to PD-1 blockade, Cancer Immunol Res, 4, 959, 10.1158/2326-6066.CIR-16-0143
Hamid, 2019, Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab, Clin Cancer Res, 25, 6061, 10.1158/1078-0432.CCR-18-3488
Carbone, 2017, First-line nivolumab in stage IV or recurrent non–small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493
Merino, 2020, Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project, J Immunother Cancer, 8, e000147, 10.1136/jitc-2019-000147
Zehir, 2017, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, 23, 703, 10.1038/nm.4333
Wu, 2019, Designing gene panels for tumor mutational burden estimation: the need to shift from “correlation” to “accuracy”, J Immunother Cancer, 7, 206, 10.1186/s40425-019-0681-2
Li, 2020, Choosing tumor mutational burden wisely for immunotherapy: a hard road to explore, Biochim Biophys Acta Rev Cancer, 1874, 188420, 10.1016/j.bbcan.2020.188420
Chan, 2019, Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann Oncol, 30, 44, 10.1093/annonc/mdy495